Idoxifene - patents, research & applications

18,892Patents

62Research papers

1,692Patents - last 3 years

0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Merck Sharp and Dohme LLC	1,469
2	Celgene Corp	838
3	Merck Patent GmbH	744
4	Merck and Co Inc	580
5	Genentech Inc	445

6	Pharmacyclics LLC	371
7	Bristol Myers Squibb Co	353
8	AstraZeneca AB	339
9	F Hoffmann La Roche AG	310
10	Organon Pharma UK Ltd	288

Explore the full landscape

This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.

Visit Cypris

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61P`	Therapeutic activity (drug indications)	16,939
2	`A61K`	Medicinal preparations	13,905
3	`C07D`	Heterocyclic compounds	9,981
4	`C07K`	Peptides	3,851
5	`C12N`	Microorganisms, enzymes	1,478

6	`G01N`	Investigating / analysing materials	1,451
7	`Y02A`	Climate change adaptation	1,270
8	`C07C`	Acyclic and carbocyclic compounds	1,206
9	`C12Q`	Measuring/testing involving enzymes	740
10	`C07F`	Organometallic compounds	699

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Most-cited patents

Patents ranked by forward citations reveal the foundational inventions the field continues to build on.

Title	Year	Assignee
Method for synthesizing midbody of idoxifene	2026	ASTATECH (CHENGDU) BIOPHARMACEUTICAL CORP.
Compositions of (Z) -idoxifene and methods of enriching same	2024	Atosa therapeutics
THERAPEUTIC AGENTS BASED ON IDOXIFENO, USEFUL IN THE TREATMENT OF OSTEOPOROSIS	2000	SMITHKLINE BEECHAM CORPORATION
METHOD OF TREATING POST MENOPAUSAL DISEASES, INCLUDING OSTEOPOROSIS USING IDOXIFENE DERIVATIVES	2000	SMITHKLINE BEECHAM CORPORATION
Route B process for idoxifene	1999	SMITHKLINE BEECHAM PLC.

Where research is gaining momentum

Research themes ranked by publication activity show where scientific interest is accelerating around this compound.

#	Research topic	Papers
1	Estrogen and related hormone effects	1
2	Genomics, phytochemicals, and oxidative stress	1
3	Microtubule and mitosis dynamics	1

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Michael Jarman	Institute of Cancer Research	13
2	Mitch Dowsett	Royal Marsden Hospital	5
3	R. Charles Coombes	Charing Cross Hospital	5
4	Ben P. Haynes	The Honourable Society of Lincoln's Inn	4
5	Brian MacDonald	Vanderbilt University Medical Center	4

6	Eliot H. Ohlstein	New Frontier	4
7	Ian R. Hardcastle	Institute of Cancer Research	4
8	Jack D. Henion	Cornell University	4
9	Maxine Gowen	New Frontier	4
10	V. Craig Jordan	Northwestern University	4

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms	2001	100	Endometrial and Cervical Cancer Treatments
Bioanalytical High-Throughput Selected Reaction Monitoring-LC/MS Determination of Selected Estrogen Receptor Modulators in Human Plasma: 2000 Samples/Day	2000	97	Advanced Proteomics Techniques and Applications
High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment	2002	88	Bone health and osteoporosis research
Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats	1998	88	Menopause: Health Impacts and Treatments
Atmospheric pressure photoionization liquid chromatographic–mass spectrometric determination of idoxifene and its metabolites in human plasma	2002	85	Mass Spectrometry Techniques and Applications

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of Idoxifene?

Idoxifene has the molecular formula C28H30INO with a molecular weight of 523.4585 g/mol. Its canonical IUPAC name is 1-[2-[4-[(E)-1-(4-iodophenyl)-2-phenylbut-1-enyl]phenoxy]ethyl]pyrrolidine.

Which companies hold the most patents related to Idoxifene?

The leading patent assignees in the Idoxifene landscape are Merck Sharp and Dohme LLC with 1469 patents, Celgene Corp with 838 patents, and Merck Patent GmbH with 744 patents. Other significant assignees include Merck and Co Inc, Genentech Inc, and Pharmacyclics LLC.

What research areas have produced publications about Idoxifene?

Published research on Idoxifene has covered several key areas. Studies have examined its effects on bone health and osteoporosis, its role as a selective estrogen receptor modulator in menopause-related treatments, endometrial disease screening in postmenopausal women, and analytical methods including bioanalytical LC/MS determination and atmospheric pressure photoionization mass spectrometry for quantifying idoxifene and its metabolites in human plasma.

Who are the most prolific authors publishing on Idoxifene?

Michael Jarman from the Institute of Cancer Research is the most prolific author, with 13 papers on Idoxifene-related topics. Other significant contributors include Mitch Dowsett from Royal Marsden Hospital and R. Charles Coombes from Charing Cross Hospital, each with 5 papers. Additional authors with 4 papers each include Ben P. Haynes, Brian MacDonald, Eliot H. Ohlstein, Ian R. Hardcastle, Jack D. Henion, Maxine Gowen, and V. Craig Jordan.

What is the patent classification distribution for Idoxifene-related intellectual property?

Idoxifene patents are predominantly classified under pharmaceutical and chemical categories. The leading CPC subclasses are A61P (Medicinal preparations) with 16939 patents, A61K (Preparations for medical purposes) with 13905 patents, and C07D (Heterocyclic compounds) with 9981 patents. Other significant subclasses include C07K (Peptide compounds), C12N (Microorganisms or enzymes), and G01N (Measuring or analyzing materials).